[April 29, 2016]

Anxiety Disorders Therapeutics Pipeline Report 2016 - Review of 45 Companies & Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Anxiety Disorders Overview
3. Therapeutics Development
4. Pipeline Products for Anxiety Disorders - Overview
5. Pipeline Products fo Anxiety Disorders - Comparative Analysis
6. Anxiety Disorders - Therapeutics under Development by Companies
7. Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes
8. Anxiety Disorders Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Anxiety Disorders - Products under Development by Companies
13. Anxiety Disorders - Products under Investigation by Universities/Institutes
14. Anxiety Disorders - Companies Involved in Therapeutics Development

• AbbVie Inc.
• Ache Laboratorios Farmaceuticos S/A
• Adamed Sp. z o.o.
• Addex Therapeutics Ltd
• Amorsa Therapeutics Inc.
• Avineuro Pharmaceuticals, Inc.
• Azevan Pharmaceuticals, Inc.
• Bionomics Limited
• Boehringer Ingelheim GmbH
• C4X Discovery Holdings PLC
• Catalyst Pharmaceutical Partners, Inc.
• Edgemont Pharmaceuticals, LLC
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gabather AB
• GW Pharmaceuticals Plc
• HolsboerMaschmeyer NeuroChemie GmbH
• Humanetics Corporation
• IntelGenx Corp.
• Intra-Cellular Therapies, Inc.
• INVENT Pharmaceuticals, Inc.
• Marinus Pharmaceuticals, Inc.
• Merz Pharma GmbH & Co. KgaA
• MI.TO. Technology S.r.L.
• Nemus Bioscience, Inc.
• Neuralstem, Inc.
• Neurelis, Inc.
• NeuroNascent, Inc.
• Newron Pharmaceuticals S.p.A.
• Nippon Chemiphar Co., Ltd.
• Novartis AG

View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005800/en/

[ Back To TMCnet.com's Homepage ]